CABALETTA BIO, INC. Investment Income, Interest
CABALETTA BIO, INC. (CABA) reported Investment Income, Interest of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- CABALETTA BIO, INC. investment income, interest for the quarter ending 2026-06-30 was $1.60M, a 13.76% increase year-over-year.
- CABALETTA BIO, INC. investment income, interest for the quarter ending 2026-03-31 was $1.08M, a 27.64% decline year-over-year.
- CABALETTA BIO, INC. investment income, interest for the quarter ending 2025-12-31 was $1.33M, a 31.90% decline year-over-year.
- CABALETTA BIO, INC. investment income, interest for the quarter ending 2025-09-30 was $1.81M, a 25.20% decline year-over-year.
- CABALETTA BIO, INC. investment income, interest for fiscal 2025 was $6.03M, a 39.84% decline from fiscal 2024.
- CABALETTA BIO, INC. investment income, interest for fiscal 2024 was $10.03M, a 43.52% increase from fiscal 2023.
- CABALETTA BIO, INC. investment income, interest for fiscal 2023 was $6.99M, a 500.09% increase from fiscal 2022.
- CABALETTA BIO, INC. investment income, interest for fiscal 2022 was $1.16M, a 4750.00% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-13 | $2.68M 10-Q · filed 2026-08-13 | $4.01M derived: sum of 3 quarters · filed 2026-08-13 | $5.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.08M 10-Q · filed 2026-05-14 | $2.40M derived: sum of 2 quarters · filed 2026-05-14 | $4.21M derived: sum of 3 quarters · filed 2026-05-14 | $5.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.13M derived: sum of 2 quarters · filed 2026-03-23 | $4.54M derived: sum of 3 quarters · filed 2026-08-13 | $6.03M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.81M 10-Q · filed 2025-11-10 | $3.22M derived: sum of 2 quarters · filed 2026-08-13 | $4.71M 10-Q · filed 2025-11-10 | $6.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.41M 10-Q · filed 2026-08-13 | $2.90M 10-Q · filed 2026-08-13 | $4.84M derived: sum of 3 quarters · filed 2026-08-13 | $7.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.49M 10-Q · filed 2026-05-14 | $3.43M derived: sum of 2 quarters · filed 2026-05-14 | $5.85M derived: sum of 3 quarters · filed 2026-05-14 | $8.53M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.36M derived: sum of 2 quarters · filed 2026-03-23 | $7.04M derived: sum of 3 quarters · filed 2026-03-23 | $10.03M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.42M 10-Q · filed 2025-11-10 | $5.09M derived: sum of 2 quarters · filed 2025-11-10 | $8.08M 10-Q · filed 2025-11-10 | $10.34M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.68M 10-Q · filed 2025-08-07 | $5.66M 10-Q · filed 2025-08-07 | $7.92M derived: sum of 3 quarters · filed 2025-08-07 | $10.14M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.98M 10-Q · filed 2025-05-15 | $5.24M derived: sum of 2 quarters · filed 2025-05-15 | $7.46M derived: sum of 3 quarters · filed 2025-05-15 | $8.87M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.48M derived: sum of 2 quarters · filed 2025-03-31 | $5.88M derived: sum of 3 quarters · filed 2025-03-31 | $6.99M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.22M 10-Q · filed 2024-11-14 | $3.62M derived: sum of 2 quarters · filed 2024-11-14 | $4.72M 10-Q · filed 2024-11-14 | $5.33M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.40M 10-Q · filed 2024-08-08 | $2.50M 10-Q · filed 2024-08-08 | $3.12M derived: sum of 3 quarters · filed 2024-08-08 | $3.47M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-15 | $1.71M derived: sum of 2 quarters · filed 2024-05-15 | $2.06M derived: sum of 3 quarters · filed 2024-05-15 | $2.21M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $610.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $961.00K derived: sum of 2 quarters · filed 2024-03-21 | $1.11M derived: sum of 3 quarters · filed 2024-03-21 | $1.16M 10-K · filed 2024-03-21 |
| 2022-09-30 | $351.00K 10-Q · filed 2023-11-09 | $501.00K derived: sum of 2 quarters · filed 2023-11-09 | $554.00K 10-Q · filed 2023-11-09 | $559.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $150.00K 10-Q · filed 2023-08-10 | $203.00K 10-Q · filed 2023-08-10 | $208.00K derived: sum of 3 quarters · filed 2023-08-10 | $211.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $53.00K 10-Q · filed 2023-05-11 | $58.00K derived: sum of 2 quarters · filed 2023-05-11 | $61.00K derived: sum of 3 quarters · filed 2023-05-11 | $67.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $8.00K derived: sum of 2 quarters · filed 2023-03-16 | $14.00K derived: sum of 3 quarters · filed 2023-03-16 | $24.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $3.00K 10-Q · filed 2022-11-10 | $9.00K derived: sum of 2 quarters · filed 2022-11-10 | $19.00K 10-Q · filed 2022-11-10 | $40.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $6.00K 10-Q · filed 2022-08-11 | $16.00K 10-Q · filed 2022-08-11 | $37.00K derived: sum of 3 quarters · filed 2022-08-11 | $60.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-12 | $31.00K derived: sum of 2 quarters · filed 2022-05-12 | $54.00K derived: sum of 3 quarters · filed 2022-05-12 | $94.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $44.00K derived: sum of 2 quarters · filed 2022-03-17 | $84.00K derived: sum of 3 quarters · filed 2022-03-17 | $494.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $23.00K 10-Q · filed 2021-11-01 | $63.00K derived: sum of 2 quarters · filed 2021-11-01 | $473.00K 10-Q · filed 2021-11-01 | $930.00K derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $40.00K 10-Q · filed 2021-08-05 | $450.00K 10-Q · filed 2021-08-05 | $907.00K derived: sum of 3 quarters · filed 2021-08-05 | $1.29M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $410.00K 10-Q · filed 2021-05-03 | $867.00K derived: sum of 2 quarters · filed 2021-05-03 | $1.25M derived: sum of 3 quarters · filed 2021-05-03 | $1.69M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $838.00K derived: sum of 2 quarters · filed 2021-03-16 | $1.28M derived: sum of 3 quarters · filed 2021-03-16 | $1.74M 10-K · filed 2021-03-16 |
| 2019-09-30 | $381.00K 10-Q · filed 2020-11-10 | $825.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.28M 10-Q · filed 2020-11-10 | $1.44M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $444.00K 10-Q · filed 2020-08-06 | $902.00K 10-Q · filed 2020-08-06 | $1.06M derived: sum of 3 quarters · filed 2020-08-06 | $1.11M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $458.00K 10-Q · filed 2020-05-12 | $618.00K derived: sum of 2 quarters · filed 2020-05-12 | $666.00K derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $208.00K derived: sum of 2 quarters · filed 2020-03-30 | $235.00K 10-K · filed 2020-03-30 | |
| 2018-09-30 | $48.00K 10-Q · filed 2019-12-05 | $75.00K 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |